Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:April 3, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:April 3, 2023Terminated
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene RearrangementsLast Updated:January 9, 2024Active, not recruiting
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:July 3, 2023Terminated
Condition(s):Locally Advanced Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Solid Tumor; Metastatic CholangiocarcinomaLast Updated:March 7, 2024Recruiting
Condition(s):Advanced CholangiocarcinomaLast Updated:February 23, 2024Approved for marketing
Condition(s):Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and CholangiocarcinomaLast Updated:December 19, 2023Completed
Condition(s):Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene TranslocationLast Updated:August 28, 2023Recruiting
Condition(s):Solid TumorsLast Updated:March 28, 2024Recruiting
Condition(s):CholangiocarcinomaLast Updated:November 18, 2023Active, not recruiting
Condition(s):Gastric Cancer; Gastroesophageal Junction AdenocarcinomaLast Updated:March 22, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.